<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>3(4)</volume><submitter>Momotow J</submitter><funding>Bristol-Myers Squibb</funding><funding>Meso Scale Diagnostics</funding><funding>Novartis</funding><journal>HemaSphere</journal><pagination>e293</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6919467</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center.</pubmed_title><pmcid>PMC6919467</pmcid><funding_grant_id>NCT02181738</funding_grant_id><pubmed_authors>Tresckow BV</pubmed_authors><pubmed_authors>Goergen H</pubmed_authors><pubmed_authors>Brockelmann PJ</pubmed_authors><pubmed_authors>Behringer K</pubmed_authors><pubmed_authors>Engert A</pubmed_authors><pubmed_authors>Momotow J</pubmed_authors><pubmed_authors>Borchmann S</pubmed_authors><pubmed_authors>Kobe C</pubmed_authors><pubmed_authors>Sasse S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center.</name><description/><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Oct</publication><modification>2026-05-07T02:08:43.051Z</modification><creation>2025-04-05T15:36:01.225Z</creation></dates><accession>S-EPMC6919467</accession><cross_references><pubmed>31942546</pubmed><doi>10.1097/HS9.0000000000000293</doi></cross_references></HashMap>